Back

Torsemide versus furosemide in patients with heart failure: a systematic review and meta-analysis.

31 August 2024 (15:00 - 15:50)
Organised by: Logo
Congress Presentation Part of: Novel and old treatments, evidence in large populations Diuretics ESC Professional Premium Access ESC Congress 2024 European Society of Cardiology

About the speaker

Photo
Doctor Raneem Afify

Malhallah (Egypt)

7 More presentations in this session

Presentation thumbnail
Ezetimibe use and mortality after myocardial infarction: a nationwide cohort study
Doctor V. Kyto (Turku, FI)
Abstract Slides Video
Presentation thumbnail
Lipid-lowering therapy with Inclisiran in the real-world setting: initial data from a national health care service
Associate Professor B. Zafrir (Haifa, IL)
Abstract Slides Video
Presentation thumbnail
Moderate-intensity statin combined with ezetimibe versus high-intensity statin monotherapy for secondary cardiovascular risk reduction: a systematic review and meta-analysis
Mr M. Kritya (Pune, IN)
Abstract Slides Video
Presentation thumbnail
Efficacy and safety of intravenous iron therapy in heart failure patients with iron deficiency: a systematic review and meta-analysis of randomized controlled trials
Doctor M. Abouzid (Poznan, PL)
Abstract Slides Video
Presentation thumbnail
Prognostic implications of guideline-directed medical therapy in functional mitral regurgitation: a meta-analysis
Doctor V. Anastasiou (Thessaloniki, GR)
Abstract Slides Video

Access the full session

Session thumbnail
Novel and old treatments, evidence in large populations

The Event

Event poster

ESC Congress 2024

31 August 2024 15:00 CET
You may be interested in
thumbnail
Congress Presentation
Torsemide versus furosemide in patients with heart failure: a systematic review and updated meta-analysis of randomised controlled trials
thumbnail
Congress Presentation
Diuresis efficacy in ambulatory congested heart failure patients: Intra -patient comparison of three diuretic regimens (DEA-HF)
thumbnail
Congress Presentation
Impact on hospitalisation and safety of high doses of torasemide in advanced or end-stage decompensated heart failure

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources